PTC Therapeutics, Inc. (PTCT) Holdings Maintained by California Public Employees Retirement System

California Public Employees Retirement System held its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,500 shares of the biopharmaceutical company’s stock at the close of the second quarter. California Public Employees Retirement System owned about 0.06% of PTC Therapeutics worth $357,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. American International Group Inc. boosted its position in shares of PTC Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 20,480 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 1,355 shares during the period. Alps Advisors Inc. boosted its position in shares of PTC Therapeutics by 5.6% in the 2nd quarter. Alps Advisors Inc. now owns 31,191 shares of the biopharmaceutical company’s stock valued at $572,000 after purchasing an additional 1,667 shares during the period. ProShare Advisors LLC boosted its position in shares of PTC Therapeutics by 8.9% in the 2nd quarter. ProShare Advisors LLC now owns 24,115 shares of the biopharmaceutical company’s stock valued at $442,000 after purchasing an additional 1,970 shares during the period. TIAA CREF Investment Management LLC boosted its position in shares of PTC Therapeutics by 3.0% in the 1st quarter. TIAA CREF Investment Management LLC now owns 96,318 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 2,774 shares during the period. Finally, Teachers Advisors LLC boosted its position in shares of PTC Therapeutics by 5.2% in the 2nd quarter. Teachers Advisors LLC now owns 61,324 shares of the biopharmaceutical company’s stock valued at $1,124,000 after purchasing an additional 3,026 shares during the period. 80.27% of the stock is owned by hedge funds and other institutional investors.

A number of analysts recently issued reports on PTCT shares. BidaskClub cut PTC Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 4th. William Blair initiated coverage on PTC Therapeutics in a research note on Wednesday, August 23rd. They set a “market perform” rating and a $17.00 price objective for the company. Zacks Investment Research raised PTC Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research note on Wednesday, August 30th. ValuEngine downgraded PTC Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 7th. Finally, Barclays PLC reaffirmed a “hold” rating and set a $22.00 price objective on shares of PTC Therapeutics in a research note on Friday, September 8th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $18.75.

PTC Therapeutics, Inc. (PTCT) opened at $16.59 on Friday. PTC Therapeutics, Inc. has a one year low of $8.12 and a one year high of $22.00. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.97 and a current ratio of 3.08.

COPYRIGHT VIOLATION NOTICE: “PTC Therapeutics, Inc. (PTCT) Holdings Maintained by California Public Employees Retirement System” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/11/26/ptc-therapeutics-inc-ptct-holdings-maintained-by-california-public-employees-retirement-system.html.

PTC Therapeutics Profile

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT).

Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply